We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Comparative analysis of idecabtagene vicleucel outcomes in high-risk versus standard-risk multiple myeloma patients, highlighting treatment implications.
No takes yet. Share an insight, caveat, or question.
Maqbool et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: